ESH MDS 2021 | Novel therapies in the future of MDS treatment
Felicitas Thol
• 22 Jan 2021
Felicitas Thol, MD, Hannover Medical School, Hannover, Germany, discusses the future of myelodysplastic syndromes (MDS) treatment at EHS MDS 2021. Dr Thol highlights promising results from trials of azacitidine plus venetoclax for high-risk MDS, as well as the possibility of APR-246 becoming an option for TP53 mutant high-risk MDS in the future. For low-risk MDS, Dr Thol talks about the development of a new ‘don’t eat me’ signal destroyer and of novel therapies targeting inflammation to prevent bone marrow failure. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.
